NCT03450330 - Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

September 3, 2019

Study Completion Date

January 10, 2020

Conditions

Nonsmall Cell Lung Cancer

Interventions

DRUG

AZD4205

Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.

Trial Locations (4)

2066

Northern Cancer Institute St Leonards, Sydney

3084

Austin Hospital, Heidelberg

Unknown

St George Hospital, Sydney

Peter MacCallum Cancer Centre, Melbourne